<DOC>
	<DOCNO>NCT03025841</DOCNO>
	<brief_summary>Pneumonia frequent infection critically ill patient remain significant challenge intensivists world-wide due persist high mortality morbidity . Compelling evidence suggest appropriate antibiotic therapy remain important intervention improve patient ' outcome , include administration suitable molecule optimize dosage regimen . A vast array pathophysiological change occur critically ill patient complicate antibiotic dosing . Knowledge pharmacokinetic pharmacodynamic property antibiotic use management critically ill patient essential select antibiotic dosing regimen , optimize patient outcome . Changes volume distribution ( Vd ) clearance ( CL ) antibiotic note patient , may affect antibiotic concentration target site . It follow pharmacodynamic parameter determine antibiotic efficacy , vary antibiotic class , may also affect . Optimization parameter necessary maximize rate response patient recovery minimize antibiotic resistance . In multicenter observational study critically ill patient normal plasma renal index admission , 65 % patient manifest augmented creatinine clearance least one occasion first seven study day . Augmented creatinine clearance may significantly impact drug pharmacokinetics variety renally eliminate pharmaceutical ( low-molecular weight heparin , aminoglycosides , glycopeptides , β-lactams ) , lead subtherapeutic concentration potentially adverse clinical outcome . Currently little data exist describe consequence augment creatinine clearance antibiotic PK . Ceftaroline ( 600 mg bid ) cephalosporin expand gram-positive activity , include MRSA penicillin-resistant streptococcus , approve US Food Drug Administration ( FDA ) October 29 , 2010 treatment acute bacterial SSSIs community-acquired bacterial pneumonia . Ceftaroline show also good activity common gram-negative respiratory pathogen ( eg , Haemophilus influenzae , Moraxella catarrhalis , Neisseria meningitidis , Pasteurella multocida ) . However , display clinically relevant activity Pseudomonas aeruginosa , Stenotrophomonas maltophilia , Acinetobacter baumannii . Ceftaroline also lack activity gram-negative organisms extended-spectrum β-lactamases . Importantly , ceftaroline appear induce AmpC β-lactamases despite MIC value susceptible range , ittheoretically avoid gram-negative bacteria know harbor inducible AmpC β-lactamases ( eg , Serratia , Proteus , Citrobacter , Morganella , Enterobacter , Providencia , P. aeruginosa ) . In patient , ceftaroline give prodrug , ceftaroline fosamil . After intravenous administration , prodrug rapidly transform plasma phosphatase enzymes bioactive metabolite . The pharmacokinetics ceftaroline evaluate single multiple dose study healthy volunteer , subject various degree renal impairment healthy elderly subject . The volume distribution equal 20.3 L , correspond extracellular fluid volume . The protein bind low ( 20 % ) . The main route elimination via renal excretion , clearance estimate to160 mL/min close creatinine clearance . The elimination half-live 2.6 h adult normal renal function . Unfortunately , PK study perform infect critically ill patient augment creatinine clearance . The best PK-PD index predict drug efficacy % Time &gt; CMI . A bacteriostatic effect achieve free drug concentration exceed MIC 30 40 % dose administration interval ( 30 40 % T &gt; MIC ) . Near maximum organism kill achieve 50 60 % T &gt; MIC ( 30 % T &gt; MIC Staphylococcus aureus ) . This project aim characterize ceftaroline PK patient early-onset pneumonia augment creatinine clearance . The choice ceftaroline justify spectrum suitable micro-organism commonly encounter early onset pneumonia , include methicillin-resistant Staphylococcus aureus . Secondary main objective predict probably reach PK-PD target use Monte Carlo simulation various scenario order identify optimal ceftaroline administration schemes critical care patient various degree renal impairment .</brief_summary>
	<brief_title>Population Pharmacokinetic ( PK ) Study Zinforo ( Ceftaroline ) Critical Care Patients With Early-onset Pneumonia Augmented Renal Clearance</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<criteria>Hospitalized ICU Under mechanical ventilation Developing earlyonset ( seven day follow hospital admission ) pneumonia cause Gram positive and/or Gram negative bacteria . Having augment renal clearance define directly measure creatinine clearance , use MDRD , equal 130 mL/min/1.73m² Having one risk factor multi drug resistant bacteria : antibiotic treatment last 3 month high level resistance unit immunosuppression one pneumonia risk factor , whose one hospitalization 48 hour past 90 day , live medical care house , chronic hemodialysis , home base wound care resistant bacteria family environment Morbidly obese subject ( BMI &gt; 40 kg/m² ) Septic shock Ceftaroline administer past 14 day inclusion Diuretic treatment Suspicion confirmation pneumonia ceftarolineresistant bacteria Known hypersensitivity due Ceftaroline cephalosporin antibiotic Known hypersensitivity due Gentamicin aminoglycosides antibiotic Hypersensitivity due beta lactamin antibiotic Anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>